Aside from maybe high school biology classes, the first time many people heard of mRNA was during the pandemic because of the ...

A research team at Florida State University's Institute of Molecular Biophysics and Department of Chemistry and Biochemistry ...

An update from Wave Life Sciences ( ($WVE) ) is now available. On December 9, 2025, Wave Life Sciences announced an ...

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA ...

Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)demonstrate ...

Stoke Therapeutics, Inc. , a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. today announced data presentations ...

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in ...

New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...

IQ Consortium experts explain how advanced chromatographic and analytical strategies are improving the bioanalysis, ...

A cross-section from a healthy brain and one with Huntington’s disease. The huntingtin protein causes nerve cells in the brain to break down and die. Jenna El-Attar/ Guest Artist Huntington’s disease ...

Arnatar Therapeutics has unveiled with $52 million in series A financing to bankroll new RNA-based therapies, including a candidate that takes aim at a rare genetic disease called Alagille syndrome ...